Cervical Dysplasia Market Overview 2030:
Cervical dysplasia is a precancerous condition characterized by the growth of abnormal cells on the surface lining of the endocervical canal or cervix. The endocervical canal is the opening between the uterus and the vagina—also known as cervical intraepithelial neoplasia. Cervical dysplasia is highly prevalent among women under the age of 30, and is strongly associated with the human papillomavirus, which is often transmitted sexually. There are no symptoms of cervical dysplasia, and the ideal way to discover it is by a routine Pap test. Moderate-to-severe cervical dysplasia requires the removal of the abnormal cells that help reduce the risk of cervical cancer.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical products for cervical dysplasia has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the cervical dysplasia market.
Top Impacting Factors
The rising prevalence of cancer in women all over the world is one of the factors acting as a driver for the cervical dysplasia market. In a report published by the WHO in 2018, over 0.57 million cases of cervical dysplasia were recorded worldwide.
Since cervical dysplasia is one of the most common HPV-associated cancer in women, the number of screenings done for the lesions caused by this disease has increased. Hence, this factor has boosted the growth of the cervical dysplasia market.
The number of government-funded screening programs for cervical dysplasia has increased over the years and led to the growth of the global market.
Moreover, increase in the number of awareness programs of cervical dysplasia for early diagnosis of this disease acts as a key driver of the market.
However, low number of cervical screenings and the lack of awareness of cervical dysplasia in developing countries impede the growth of the cervical dysplasia market.
Key Market Trends
In March 2019, the first government campaign that helped create awareness about cervical dysplasia with the use of smear tests was launched by Public Health England. This awareness program helped reduce the embarrassment associated with Pap tests.
In 2017, a community called “Smear your Mea” was founded. New Zealand Health funded this community to encourage women to have smear tests and reduce their chances of developing uterine and cervical cancers.
In March 2018, the sexually transmitted infections portfolio of Fast Trach Diagnostics was expanded with the addition of human papillomavirus (HPV) tests. These new series of tests include real-time PCR kits that help detect HPV18, HPV16, HPV12, and other subtypes of the human papillomavirus.
Rising initiatives by key players to develop better colposcope devices can propel the growth of the cervical dysplasia market during the forecast period. Colposcope devices are known to be the major diagnostic devices that help diagnose cervical dysplasia.
Key Benefits of the Report
- This study presents the analytical depiction of the cervical dysplasia industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Cervical Dysplasia Report
- Which are the leading players active in the cervical dysplasia market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the cervical dysplasia market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What is cervical dysplasia?
- What are the current and predicted trends of the market?
Cervical Dysplasia Market, by Diagnostic Type Report Highlights
| Aspects | Details |
 By Diagnostic Type |
|
 By Treatment Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | Qiagen N.V., OncoHealth Corporation, Inc., Hologic, Inc., Abbott Laboratories, Becton and Dickinson Company, Karl Kaps GmbH and Co., Micromedic Technologies Ltd., CooperSurgical Inc., Quest Diagnostics, DYSIS Medical Ltd |
Loading Table Of Content...
